{"ticker": {"uuid": "671a5839-8f9a-4bbb-93ae-2f45d9a5a1ee", "symbol": "NRSN", "name": "Neurosense Therapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "NeuroSense Reports 14.9-Month Median Survival Benefit for PrimeC", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPY0FNVHppTVVuZV9SZWhiM2Ffcm1Gc1JSV21mU3RZUTBSWEtUcU10XzlMcW1MbEhlcGJFM1VZNlRQSGNvNGx5cnJlWWU4WXBUZkVObXo2T2kxcm82SWRGRFhNTGRIWmNRNzNuY2JUeGJfclBkcmtuem5vSU5ZMnJXNU0yT1gzUzJUUzVieV9FT29QcUVkUE1OaVQtT3BmdFVqd25hSU9wcFZubnNlY3ZjSFNFMjllTkEzOVpHag?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T12:30:00+00:00", "published_display": "22 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug", "summary": "NeuroSense Therapeutics announced its intent to file a New Drug Submission (NDS) with Health Canada for PrimeC, its lead candidate for amyotrophic lateral sclerosis (ALS). This follows a positive Pre-NDS meeting where updated Phase 2b data, showing a 14.9-month median survival be", "url": "https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-c3a28f21e669.html", "source_name": "Stock Titan", "published_at": "2026-07-22T12:40:20", "published_display": "22 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS", "summary": "NeuroSense Therapeutics announced its intention to file a New Drug Submission (NDS) with Health Canada for PrimeC, its treatment for amyotrophic lateral sclerosis (ALS). This decision follows a constructive pre-NDS meeting and is supported by additional data from the Phase 2b PAR", "url": "https://www.prnewswire.com/news-releases/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-302832117.html", "source_name": "PR Newswire", "published_at": "2026-07-22T08:30:00", "published_display": "22 Jul 2026 08:30", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66 - Calendar Spread Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNX3ZJUmg4Sk5sU044dDcyZTVRUVh1Qm85ZTZTR1U2M2FNNnlwRDUzWHRob2U2RWJjWHVmU1psV0VOcTZMdzd5YzI1SG9paXRNUkVXemxlcXk3LTY0MG1nTmpROEE5NE5QVFhZd2lHZmJRb3hwTnM1b2FYa2JkRV9nUmlqOGs3dkU4aGVjblhaZE5rYURxTFdFQi1SN2FUaEFzSkJKUXhhTjlXM1l2MFdmcUtSZkJodw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-17T00:48:10+00:00", "published_display": "17 Jul 2026 00:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroSense joins ALS expert webinar on PrimeC and Phase 3 plans", "summary": "NeuroSense Therapeutics (NRSN) will participate in a Roth Capital Partners webinar on July 8, 2026, focusing on ALS treatment, clinical trial endpoints, and its drug candidate, PrimeC. The webinar will feature ALS expert Professor Jeremy Shefner and NeuroSense CEO Alon Ben-Noon, ", "url": "https://www.stocktitan.net/news/NRSN/neuro-sense-to-participate-in-roth-hosted-kol-webinar-on-the-future-o3fbs0ol6cac.html", "source_name": "Stock Titan", "published_at": "2026-07-07T07:10:12", "published_display": "07 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: \"A Quest to Outrun ALS\"", "summary": "NeuroSense Therapeutics will participate in a Roth Capital Partners-hosted KOL webinar titled \"A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)\" on Wednesday, July 8, 2026, at 11:00 a.m. ET. The webinar will feature ALS expert Professor Jeremy Shefner and NeuroSense CEO Alon", "url": "https://www.prnewswire.com/news-releases/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatment-a-quest-to-outrun-als-302818300.html", "source_name": "PR Newswire", "published_at": "2026-07-06T13:10:54", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSN", "summary": "This article provides financial information for NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, indicating no current trades at the time of publication. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:10:19", "published_display": "04 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings", "summary": "This page provides access to NeuroSense Therapeutics Ltd.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. The documents detail the company's financial performance, operational updates, and progress of its drug PrimeC, particularly its effectiveness i", "url": "https://www.tradingview.com/symbols/BOATS-NRSNW/documents/", "source_name": "TradingView", "published_at": "2026-07-03T23:10:19", "published_display": "03 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense bolsters case for multi-target Alzheimer\u2019s strategy", "summary": "NeuroSense Therapeutics has reported positive biomarker findings from its Phase 2 RoAD study for PrimeC in Alzheimer\u2019s disease, suggesting the therapy may be acting on shared neurodegeneration mechanisms across different diseases like ALS and Alzheimer's. The company's multi-targ", "url": "https://longevity.technology/news/neurosense-bolsters-case-for-multi-target-alzheimers-strategy/", "source_name": "Longevity.Technology", "published_at": "2026-07-03T16:04:42", "published_display": "03 Jul 2026 16:04", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurosense-says-phase-2b-trial-140042988.html", "source_name": "MT Newswires", "published_at": "2026-06-29T14:00:42+00:00", "published_display": "29 Jun 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS", "summary": "NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC for ALS successfully met its primary efficacy endpoint by demonstrating a statistically significant reduction in TDP-43 levels, a key pathological hallmark of ALS. This marks the first randomized, double", "url": "https://www.prnewswire.com/news-releases/neurosense-achieves-primary-endpoint-in-phase-2b-als-study-with-statistically-significant-reduction-of-tdp-43-the-defining-pathological-hallmark-of-als-302813175.html", "source_name": "PR Newswire", "published_at": "2026-06-29T13:13:18", "published_display": "29 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3", "summary": "NeuroSense Therapeutics announced its Phase 2b trial of PrimeC for ALS successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43, a key pathological hallmark of the disease. This reduction deepened and remained significant over ", "url": "https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-2b20a0ee357a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:13:18", "published_display": "29 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "This article provides a specific financial metric, the \"Price to sales forward,\" for NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW). It appears to be a stub or a data point from a financial platform, showing no additional details or commentary beyond the metric itself. The content p", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:40:38", "published_display": "27 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease", "summary": "NeuroSense Therapeutics announced positive biomarker findings from its Phase 2 RoAD study of PrimeC in Alzheimer's disease (AD). The study, though small, showed PrimeC was associated with changes in key AD hallmark proteins like tau and amyloid-beta, as well as other neurodegener", "url": "https://www.prnewswire.com/il/news-releases/neurosense-reports-positive-biomarker-findings-from-phase-2-road-proof-of-concept-study-of-primec-in-alzheimers-disease-302810686.html", "source_name": "PR Newswire", "published_at": "2026-06-27T07:10:12", "published_display": "27 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer\u2019s disease", "summary": "NeuroSense Therapeutics has announced promising biomarker findings from its Phase 2 RoAD study for PrimeC in Alzheimer\u2019s disease. The small, exploratory study involving eight participants showed changes across multiple neurodegenerative disease pathways, supporting PrimeC's multi", "url": "https://www.biospectrumasia.com/news/26/27922/neurosense-reports-phase-2-biomarker-findings-for-primec-in-alzheimers-disease.html", "source_name": "BioSpectrum Asia", "published_at": "2026-06-26T05:39:21", "published_display": "26 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN)", "summary": "This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) stock performance, financial actuals, and analyst estimates. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along wit", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:18", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "This article provides financial information for NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW), specifically its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data display from TradingView, indicating that the value and change ", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:01", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "This article provides the enterprise value to revenue forward for NeuroSense Therapeutics Ltd., traded under the NASDAQ symbol NRSNW. The content primarily focuses on financial data for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:44", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRSN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for NeuroSense Therapeutics Ltd. (NRSN) stock for 2027. It includes analyst ratings, earnings estimates, historical price performance, and answers frequently asked questions about the company's financials, market capitalization, e", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:02", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Neurosense Therapeutics Ltd. \u2013 FWB:H1Z", "summary": "This article focuses on the number of shareholders for Neurosense Therapeutics Ltd. (FWB:H1Z) on the Frankfurt Stock Exchange. It provides a placeholder for data regarding shareholder numbers, changes, and percentage changes over a specified period. The content is primarily a dat", "url": "https://www.tradingview.com/symbols/FWB-H1Z/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-25T15:11:02", "published_display": "25 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (Nasdaq:NRSN) - Stock Analysis", "summary": "NeuroSense Therapeutics (Nasdaq:NRSN) is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease using its lead drug candidate, PrimeC. The company has reported positive biomarker and long-term survi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrsn/neurosense-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-25T13:40:41", "published_display": "25 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer\u2019s", "summary": "NeuroSense Therapeutics (NRSN) announced positive early biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer\u2019s disease. The study, involving eight patients with 12-month follow-up data from three, showed changes in key Alzheimer\u2019s biomarkers and ", "url": "https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-7ea2a7eb0631.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:11:01", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "The article displays the enterprise value to EBITDA forward for NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW). It appears to be an unpopulated data point or a financial metric overview from TradingView, indicating no current trades or specific values for this financial ratio.", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:10:50", "published_display": "25 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Q2 2025 Earnings: EPS Beat Amid Pre-Revenue Phase; Stock Declines - Net Income Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQOHk5M3dUN3VkTzliMFh3S0xIam1TZG85V01xUjhGQ1NNOURHVGpQeGp4aFZVMWt2S1V5Q3JTNVppcWFBRTFtTUpVYTg4ekRueDlEanRIdmFYQk9tbmcxc19NaU55RC1iS2pCVy05eEsyUkxDOWE1WXNaSS1FYnJPMk0tUTVacGJnTHU4TUR0TXFaazQ1Zm1mbDhpU043UDB3Z3VXZFpJZ0JyRThYQVUwWHU3eUZhalAwSVZNRFoyMjRidmtJRFNMR0tlZzg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/everythingals-host-neurosense-community-event-130000140.html", "source_name": "PR Newswire", "published_at": "2026-06-22T13:00:00+00:00", "published_display": "22 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALS community event puts NeuroSense\u2019s PrimeC data in focus June 24", "summary": "NeuroSense Therapeutics announced that EverythingALS will host an online event on June 24, 2026, at 7 pm ET, focusing on emerging data for PrimeC in ALS treatment. The session will feature Professor Jeffrey Rosenfeld and NeuroSense CEO Alon Ben-Noon, aiming to inform ALS patients", "url": "https://www.stocktitan.net/news/NRSN/everything-als-to-host-neuro-sense-in-a-community-event-named-prime-go9pox954noi.html", "source_name": "Stock Titan", "published_at": "2026-06-22T09:00:00", "published_display": "22 Jun 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRSN Q1'26 Earnings: EPS estimate is (0.08) USD", "summary": "NeuroSense Therapeutics Ltd. (NRSN) is expected to announce its Q1'26 earnings on June 22nd. The revenue estimate for the quarter is $514.10 thousand, with an anticipated EPS of ($0.08) USD. The article provides a table detailing past and estimated revenue and EPS figures.", "url": "https://www.tradingview.com/news/tradingview:4e6d787513ba2:0-nrsn-q1-26-earnings-eps-estimate-is-0-08-usd/", "source_name": "TradingView", "published_at": "2026-06-19T10:40:17", "published_display": "19 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Neurosense Therapeutics Ltd (NRSN)'s dividend and stock split history. It indicates that the company has not distributed dividends in the past five years and has no recorded stock split data. The current stock price and market capitalization a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:23", "published_display": "19 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution \u2014 TradingKey", "summary": "This article from TradingKey concerns Neurosense Therapeutics Ltd (NRSN) and its revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides general c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsn/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:23", "published_display": "19 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Neurosense Therapeutics Ltd (NRSN), outlining both major individual and corporate shareholders, as well as institutional holdings. Key individual investors like Ben-Noon (Alon) and Rimon Gold Assets Ltd hold significant proportion", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsn/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:24", "published_display": "19 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Neurosense Therapeutics Ltd (NRSNW), indicating a current score of 0.00 with no change from the previous score. It lists several institutional shareholders and their recent activity, including Clear Street LL", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T18:10:25", "published_display": "18 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSNW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Neurosense Therapeutics Ltd (NRSNW). It indicates that relevant data for EPS, revenue, and net profit forecasting has not been disclosed by the company yet. The stock is currently trading at $0.091, with a 9.53% increase.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsnw/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T17:10:25", "published_display": "18 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSNW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Neurosense Therapeutics Ltd (NRSNW), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it indicates that relevant data for these metrics have not yet been disclosed by the company. The current stock price for NRSN", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsnw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T17:10:25", "published_display": "18 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) CFO acquires 250,000 shares in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQeVpieUJ0NkFRUzRPV2pGWllDLWRJbG9IYjVuSUd2eXI2OUhhVk84c1JtR2ZXbVRZaVBMdmh1TFZXTUItdU1JVXI1OHZVNFVnN3hRNzN3QjFZQzFHU2ZEeXQ5aTM5Tm5JZWsxREZqLTBFQUcwTlZpQlRBVWVQbTR5VmdZQmlrM0FvTFh6TWc0dzlkX0ZHV0xBcVduTmRPb1dPWXItNENSaEltMzZOVzUyb2thbFFibXlOTHNySXBBcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) CEO acquires 250,000 shares in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNYTNaUG4wVHV3UHpPcTVTSEZVUXJwcUp5MXRqdG91MzdqY0NuaHA5WEYwLXhyemhHU3k0RF9vaFFSWGxKTnFleHZLM2dDTDdrMmJUQVBQSkJ1Zk1JdGhNWGtpa1J6VDNPaUZGZUhWUEx5QTRIb1pTeWl2aUpibFVzeldlS3dCSEM3OXJEYjd4S1NYa05BNjBSY0lXT05Wd19ab3I2R3ltOWdVeGMwLVRUbUIxU1h4T2U3YkprSmpTcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Gets South Korean Patent for ALS Drug Candidate PrimeC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurosense-therapeutics-gets-south-korean-132904397.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:29:04+00:00", "published_display": "11 Jun 2026 13:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurosense-granted-south-korean-patent-130000100.html", "source_name": "PR Newswire", "published_at": "2026-06-11T13:00:00+00:00", "published_display": "11 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Receives Japanese Patent for PrimeC to Treat ALS", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurosense-therapeutics-receives-japanese-patent-133940662.html", "source_name": "MT Newswires", "published_at": "2026-06-09T13:39:40+00:00", "published_display": "09 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Faces 4.5% Decline\u2014Key Support at $0.78 Holds the Line - Growth ETF", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNMURic0xCMGpXYXBsRXNQMXZ4TWUybElZMk1FZmJaeFZyVmEwOTZlQjVGVU41bi1aQ2E2S3FBeEpDRkgzb3g2Y0ZlRE9PZ05iR1hycXAzbldlX0QxOTN5ZEZqa0R4TmZZNWJFblVCcTVBbFN1cUxlQXE0d1I2bkliS09rVXBkUEh2RjJSbDQ3SzdIVjgwakMzU0Y3cjJ4ZEYwZTEzNnNKbUc5Mmcwb2lCVEJnVnhFbXdreDZjTzYyM1lTTHZCRU9MZXZB?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Edges Higher, Testing Resistance at $0.95 - CTA Positioning", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSE1xbE9aalNpM0dzaXhOa2JSTGtCSE1EUlJoYlRUb3NQaC1zYkVodTJ2R0FqLUlkcnVIaU1EUGhjWjdmR0hMck55dFhaOVZDN3J6cjBOVml4Y1M0SU5ocTdlajJhZ3pwZ055VlpyWEE3NV9XX2pmVjNKSHRmMFhkVW1kSDN0ZHFQNGVBVXhpQXM3a2J0OHdmckZCNEFZRTZsLWpTbVBHbDNONlVs?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroSense Announces Pricing of Insider-Led PIPE Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQYVFzSFl0ajhHVUszQjRTeEIxYjc0bW9wS1o2Q0ctQ3R6SkF0cEI0SmR1Ym93VGNLTDZwMU16T3h3VUNaNTBoLWlSdXZ2Q2RUZVljcnAxUjRpd2xKNGdpZGFmd0pZa1BadmZVeDNYOXI5MURqdldsRFZILTlrUkVyZWhEUllmSHdtM19PMlFfOF9UWEtlVTRDSXZFaGRFbUZRenl5TngxTTRXeTZ2blVoeEJMczQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Brazil grants NeuroSense ALS drug patent protection through 2042", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPQl83RWcyelg4aVZ5RVhtN1FwS1FQTVFyQTJNb1EySFpxNUttclg3VGVMSlAtX1ZldlpNbG12LVBwNTduUzc0c0lUSE1IdE00c00tMW1XdDUwTzU4WG9mbElNci1fUEpmRDRTSDJmTHF3NE5EQ0plZDlydVUtY2FDZlllVDlyekNwTmhQbFdUSHdsMzg4NlN0cUZlczlnWEFLd2F6WHdpQklVZ25S?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxOQ3puQUwyd0ZhZlZITUJQcXN4cjdocjB5a19ESzBxSms0U3RReFdBXzhCS3FxMkNOUDl0Q2FNTHdBenJLeUZjc2NEaHNuQmdnbW9iVFFOUkFIM2NiTHg0UURZa21WdUkwVWhqNmpoWUxaLXBiYkVXbFFYSDJnV1BJRGdoX3NfeGtYN1FnTHQ2bHV6OVpfS3IxUlVhSk55WGhNSkxEaUJHWndxT21OSm50eWl5bjdnUEZNcm4tNUdaRThtSjRLX0h0eGhBVE9uUUpDWTFGdjBsZHREZk9TY083M3dR?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NeuroSense Provides Business Update and Progress for the First Half of 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNMXYxSEs5T2tJVVdyRXZGSl9ad3JZdGNiTHJ5Um1zYmFSckFPM2p6VnBfM3VHclJkNHB4Z0RoV3J3QTFTOFVBVWczeldzei1aenJSUER0OUNES0IzRTRzNDB0aF91RG9uTG1vN09YOU80NVZKMi1jUE1EX1NwRy1WeWZaS1FwSWZzbXpzOEFteHA0Rm9TMUFwQXk4QS1QTUlpTVhhVXhfYVp5R1lxLXFaQnEySl9odmp2WDBMM1V0RmlOYy1QNjM0OXluNA?oc=5", "source_name": "PR Newswire", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9SSXRYZzJvMHBzZFNJMkVZUTVrR0k0UGdta3F6YjlVVUtYQUZranFGcXpCSUt1T0UtN3JhNDJPVEw3bjFhUWp5emZ6SjR0NVdKd3dBMG1udTNHUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-12-10T01:38:46+00:00", "published_display": "10 Dec 2021 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "NeuroSense Reports 14.9-Month Median Survival Benefit for PrimeC", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPY0FNVHppTVVuZV9SZWhiM2Ffcm1Gc1JSV21mU3RZUTBSWEtUcU10XzlMcW1MbEhlcGJFM1VZNlRQSGNvNGx5cnJlWWU4WXBUZkVObXo2T2kxcm82SWRGRFhNTGRIWmNRNzNuY2JUeGJfclBkcmtuem5vSU5ZMnJXNU0yT1gzUzJUUzVieV9FT29QcUVkUE1OaVQtT3BmdFVqd25hSU9wcFZubnNlY3ZjSFNFMjllTkEzOVpHag?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T12:30:00+00:00", "published_display": "22 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug", "summary": "NeuroSense Therapeutics announced its intent to file a New Drug Submission (NDS) with Health Canada for PrimeC, its lead candidate for amyotrophic lateral sclerosis (ALS). This follows a positive Pre-NDS meeting where updated Phase 2b data, showing a 14.9-month median survival be", "url": "https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-c3a28f21e669.html", "source_name": "Stock Titan", "published_at": "2026-07-22T12:40:20", "published_display": "22 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS", "summary": "NeuroSense Therapeutics announced its intention to file a New Drug Submission (NDS) with Health Canada for PrimeC, its treatment for amyotrophic lateral sclerosis (ALS). This decision follows a constructive pre-NDS meeting and is supported by additional data from the Phase 2b PAR", "url": "https://www.prnewswire.com/news-releases/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-302832117.html", "source_name": "PR Newswire", "published_at": "2026-07-22T08:30:00", "published_display": "22 Jul 2026 08:30", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66 - Calendar Spread Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNX3ZJUmg4Sk5sU044dDcyZTVRUVh1Qm85ZTZTR1U2M2FNNnlwRDUzWHRob2U2RWJjWHVmU1psV0VOcTZMdzd5YzI1SG9paXRNUkVXemxlcXk3LTY0MG1nTmpROEE5NE5QVFhZd2lHZmJRb3hwTnM1b2FYa2JkRV9nUmlqOGs3dkU4aGVjblhaZE5rYURxTFdFQi1SN2FUaEFzSkJKUXhhTjlXM1l2MFdmcUtSZkJodw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-17T00:48:10+00:00", "published_display": "17 Jul 2026 00:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense joins ALS expert webinar on PrimeC and Phase 3 plans", "summary": "NeuroSense Therapeutics (NRSN) will participate in a Roth Capital Partners webinar on July 8, 2026, focusing on ALS treatment, clinical trial endpoints, and its drug candidate, PrimeC. The webinar will feature ALS expert Professor Jeremy Shefner and NeuroSense CEO Alon Ben-Noon, ", "url": "https://www.stocktitan.net/news/NRSN/neuro-sense-to-participate-in-roth-hosted-kol-webinar-on-the-future-o3fbs0ol6cac.html", "source_name": "Stock Titan", "published_at": "2026-07-07T07:10:12", "published_display": "07 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: \"A Quest to Outrun ALS\"", "summary": "NeuroSense Therapeutics will participate in a Roth Capital Partners-hosted KOL webinar titled \"A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)\" on Wednesday, July 8, 2026, at 11:00 a.m. ET. The webinar will feature ALS expert Professor Jeremy Shefner and NeuroSense CEO Alon", "url": "https://www.prnewswire.com/news-releases/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatment-a-quest-to-outrun-als-302818300.html", "source_name": "PR Newswire", "published_at": "2026-07-06T13:10:54", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSN", "summary": "This article provides financial information for NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, indicating no current trades at the time of publication. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:10:19", "published_display": "04 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings", "summary": "This page provides access to NeuroSense Therapeutics Ltd.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. The documents detail the company's financial performance, operational updates, and progress of its drug PrimeC, particularly its effectiveness i", "url": "https://www.tradingview.com/symbols/BOATS-NRSNW/documents/", "source_name": "TradingView", "published_at": "2026-07-03T23:10:19", "published_display": "03 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense bolsters case for multi-target Alzheimer\u2019s strategy", "summary": "NeuroSense Therapeutics has reported positive biomarker findings from its Phase 2 RoAD study for PrimeC in Alzheimer\u2019s disease, suggesting the therapy may be acting on shared neurodegeneration mechanisms across different diseases like ALS and Alzheimer's. The company's multi-targ", "url": "https://longevity.technology/news/neurosense-bolsters-case-for-multi-target-alzheimers-strategy/", "source_name": "Longevity.Technology", "published_at": "2026-07-03T16:04:42", "published_display": "03 Jul 2026 16:04", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurosense-says-phase-2b-trial-140042988.html", "source_name": "MT Newswires", "published_at": "2026-06-29T14:00:42+00:00", "published_display": "29 Jun 2026 14:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS", "summary": "NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC for ALS successfully met its primary efficacy endpoint by demonstrating a statistically significant reduction in TDP-43 levels, a key pathological hallmark of ALS. This marks the first randomized, double", "url": "https://www.prnewswire.com/news-releases/neurosense-achieves-primary-endpoint-in-phase-2b-als-study-with-statistically-significant-reduction-of-tdp-43-the-defining-pathological-hallmark-of-als-302813175.html", "source_name": "PR Newswire", "published_at": "2026-06-29T13:13:18", "published_display": "29 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3", "summary": "NeuroSense Therapeutics announced its Phase 2b trial of PrimeC for ALS successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43, a key pathological hallmark of the disease. This reduction deepened and remained significant over ", "url": "https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-2b20a0ee357a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:13:18", "published_display": "29 Jun 2026 13:13", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "This article provides a specific financial metric, the \"Price to sales forward,\" for NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW). It appears to be a stub or a data point from a financial platform, showing no additional details or commentary beyond the metric itself. The content p", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:40:38", "published_display": "27 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease", "summary": "NeuroSense Therapeutics announced positive biomarker findings from its Phase 2 RoAD study of PrimeC in Alzheimer's disease (AD). The study, though small, showed PrimeC was associated with changes in key AD hallmark proteins like tau and amyloid-beta, as well as other neurodegener", "url": "https://www.prnewswire.com/il/news-releases/neurosense-reports-positive-biomarker-findings-from-phase-2-road-proof-of-concept-study-of-primec-in-alzheimers-disease-302810686.html", "source_name": "PR Newswire", "published_at": "2026-06-27T07:10:12", "published_display": "27 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer\u2019s disease", "summary": "NeuroSense Therapeutics has announced promising biomarker findings from its Phase 2 RoAD study for PrimeC in Alzheimer\u2019s disease. The small, exploratory study involving eight participants showed changes across multiple neurodegenerative disease pathways, supporting PrimeC's multi", "url": "https://www.biospectrumasia.com/news/26/27922/neurosense-reports-phase-2-biomarker-findings-for-primec-in-alzheimers-disease.html", "source_name": "BioSpectrum Asia", "published_at": "2026-06-26T05:39:21", "published_display": "26 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN)", "summary": "This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) stock performance, financial actuals, and analyst estimates. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along wit", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:18", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "This article provides financial information for NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW), specifically its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data display from TradingView, indicating that the value and change ", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:01", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "This article provides the enterprise value to revenue forward for NeuroSense Therapeutics Ltd., traded under the NASDAQ symbol NRSNW. The content primarily focuses on financial data for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:44", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRSN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for NeuroSense Therapeutics Ltd. (NRSN) stock for 2027. It includes analyst ratings, earnings estimates, historical price performance, and answers frequently asked questions about the company's financials, market capitalization, e", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:02", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Neurosense Therapeutics Ltd. \u2013 FWB:H1Z", "summary": "This article focuses on the number of shareholders for Neurosense Therapeutics Ltd. (FWB:H1Z) on the Frankfurt Stock Exchange. It provides a placeholder for data regarding shareholder numbers, changes, and percentage changes over a specified period. The content is primarily a dat", "url": "https://www.tradingview.com/symbols/FWB-H1Z/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-25T15:11:02", "published_display": "25 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (Nasdaq:NRSN) - Stock Analysis", "summary": "NeuroSense Therapeutics (Nasdaq:NRSN) is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease using its lead drug candidate, PrimeC. The company has reported positive biomarker and long-term survi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrsn/neurosense-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-25T13:40:41", "published_display": "25 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer\u2019s", "summary": "NeuroSense Therapeutics (NRSN) announced positive early biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer\u2019s disease. The study, involving eight patients with 12-month follow-up data from three, showed changes in key Alzheimer\u2019s biomarkers and ", "url": "https://www.stocktitan.net/sec-filings/NRSN/6-k-neuro-sense-therapeutics-ltd-current-report-foreign-issuer-7ea2a7eb0631.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:11:01", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. \u2013 NASDAQ:NRSNW", "summary": "The article displays the enterprise value to EBITDA forward for NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW). It appears to be an unpopulated data point or a financial metric overview from TradingView, indicating no current trades or specific values for this financial ratio.", "url": "https://www.tradingview.com/symbols/NASDAQ-NRSNW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:10:50", "published_display": "25 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Q2 2025 Earnings: EPS Beat Amid Pre-Revenue Phase; Stock Declines - Net Income Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQOHk5M3dUN3VkTzliMFh3S0xIam1TZG85V01xUjhGQ1NNOURHVGpQeGp4aFZVMWt2S1V5Q3JTNVppcWFBRTFtTUpVYTg4ekRueDlEanRIdmFYQk9tbmcxc19NaU55RC1iS2pCVy05eEsyUkxDOWE1WXNaSS1FYnJPMk0tUTVacGJnTHU4TUR0TXFaazQ1Zm1mbDhpU043UDB3Z3VXZFpJZ0JyRThYQVUwWHU3eUZhalAwSVZNRFoyMjRidmtJRFNMR0tlZzg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/everythingals-host-neurosense-community-event-130000140.html", "source_name": "PR Newswire", "published_at": "2026-06-22T13:00:00+00:00", "published_display": "22 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALS community event puts NeuroSense\u2019s PrimeC data in focus June 24", "summary": "NeuroSense Therapeutics announced that EverythingALS will host an online event on June 24, 2026, at 7 pm ET, focusing on emerging data for PrimeC in ALS treatment. The session will feature Professor Jeffrey Rosenfeld and NeuroSense CEO Alon Ben-Noon, aiming to inform ALS patients", "url": "https://www.stocktitan.net/news/NRSN/everything-als-to-host-neuro-sense-in-a-community-event-named-prime-go9pox954noi.html", "source_name": "Stock Titan", "published_at": "2026-06-22T09:00:00", "published_display": "22 Jun 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRSN Q1'26 Earnings: EPS estimate is (0.08) USD", "summary": "NeuroSense Therapeutics Ltd. (NRSN) is expected to announce its Q1'26 earnings on June 22nd. The revenue estimate for the quarter is $514.10 thousand, with an anticipated EPS of ($0.08) USD. The article provides a table detailing past and estimated revenue and EPS figures.", "url": "https://www.tradingview.com/news/tradingview:4e6d787513ba2:0-nrsn-q1-26-earnings-eps-estimate-is-0-08-usd/", "source_name": "TradingView", "published_at": "2026-06-19T10:40:17", "published_display": "19 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Neurosense Therapeutics Ltd (NRSN)'s dividend and stock split history. It indicates that the company has not distributed dividends in the past five years and has no recorded stock split data. The current stock price and market capitalization a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:23", "published_display": "19 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution \u2014 TradingKey", "summary": "This article from TradingKey concerns Neurosense Therapeutics Ltd (NRSN) and its revenue breakdown. However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides general c", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsn/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:23", "published_display": "19 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Neurosense Therapeutics Ltd (NRSN), outlining both major individual and corporate shareholders, as well as institutional holdings. Key individual investors like Ben-Noon (Alon) and Rimon Gold Assets Ltd hold significant proportion", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsn/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T01:39:24", "published_display": "19 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Neurosense Therapeutics Ltd (NRSNW), indicating a current score of 0.00 with no change from the previous score. It lists several institutional shareholders and their recent activity, including Clear Street LL", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T18:10:25", "published_display": "18 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSNW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Neurosense Therapeutics Ltd (NRSNW). It indicates that relevant data for EPS, revenue, and net profit forecasting has not been disclosed by the company yet. The stock is currently trading at $0.091, with a 9.53% increase.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsnw/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T17:10:25", "published_display": "18 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurosense Therapeutics Ltd (NRSNW) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Neurosense Therapeutics Ltd (NRSNW), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it indicates that relevant data for these metrics have not yet been disclosed by the company. The current stock price for NRSN", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrsnw/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T17:10:25", "published_display": "18 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) CFO acquires 250,000 shares in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQeVpieUJ0NkFRUzRPV2pGWllDLWRJbG9IYjVuSUd2eXI2OUhhVk84c1JtR2ZXbVRZaVBMdmh1TFZXTUItdU1JVXI1OHZVNFVnN3hRNzN3QjFZQzFHU2ZEeXQ5aTM5Tm5JZWsxREZqLTBFQUcwTlZpQlRBVWVQbTR5VmdZQmlrM0FvTFh6TWc0dzlkX0ZHV0xBcVduTmRPb1dPWXItNENSaEltMzZOVzUyb2thbFFibXlOTHNySXBBcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense (NRSN) CEO acquires 250,000 shares in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNYTNaUG4wVHV3UHpPcTVTSEZVUXJwcUp5MXRqdG91MzdqY0NuaHA5WEYwLXhyemhHU3k0RF9vaFFSWGxKTnFleHZLM2dDTDdrMmJUQVBQSkJ1Zk1JdGhNWGtpa1J6VDNPaUZGZUhWUEx5QTRIb1pTeWl2aUpibFVzeldlS3dCSEM3OXJEYjd4S1NYa05BNjBSY0lXT05Wd19ab3I2R3ltOWdVeGMwLVRUbUIxU1h4T2U3YkprSmpTcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Gets South Korean Patent for ALS Drug Candidate PrimeC", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurosense-therapeutics-gets-south-korean-132904397.html", "source_name": "MT Newswires", "published_at": "2026-06-11T13:29:04+00:00", "published_display": "11 Jun 2026 13:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurosense-granted-south-korean-patent-130000100.html", "source_name": "PR Newswire", "published_at": "2026-06-11T13:00:00+00:00", "published_display": "11 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Receives Japanese Patent for PrimeC to Treat ALS", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/neurosense-therapeutics-receives-japanese-patent-133940662.html", "source_name": "MT Newswires", "published_at": "2026-06-09T13:39:40+00:00", "published_display": "09 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Faces 4.5% Decline\u2014Key Support at $0.78 Holds the Line - Growth ETF", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNMURic0xCMGpXYXBsRXNQMXZ4TWUybElZMk1FZmJaeFZyVmEwOTZlQjVGVU41bi1aQ2E2S3FBeEpDRkgzb3g2Y0ZlRE9PZ05iR1hycXAzbldlX0QxOTN5ZEZqa0R4TmZZNWJFblVCcTVBbFN1cUxlQXE0d1I2bkliS09rVXBkUEh2RjJSbDQ3SzdIVjgwakMzU0Y3cjJ4ZEYwZTEzNnNKbUc5Mmcwb2lCVEJnVnhFbXdreDZjTzYyM1lTTHZCRU9MZXZB?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Edges Higher, Testing Resistance at $0.95 - CTA Positioning", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSE1xbE9aalNpM0dzaXhOa2JSTGtCSE1EUlJoYlRUb3NQaC1zYkVodTJ2R0FqLUlkcnVIaU1EUGhjWjdmR0hMck55dFhaOVZDN3J6cjBOVml4Y1M0SU5ocTdlajJhZ3pwZ055VlpyWEE3NV9XX2pmVjNKSHRmMFhkVW1kSDN0ZHFQNGVBVXhpQXM3a2J0OHdmckZCNEFZRTZsLWpTbVBHbDNONlVs?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Announces Pricing of Insider-Led PIPE Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQYVFzSFl0ajhHVUszQjRTeEIxYjc0bW9wS1o2Q0ctQ3R6SkF0cEI0SmR1Ym93VGNLTDZwMU16T3h3VUNaNTBoLWlSdXZ2Q2RUZVljcnAxUjRpd2xKNGdpZGFmd0pZa1BadmZVeDNYOXI5MURqdldsRFZILTlrUkVyZWhEUllmSHdtM19PMlFfOF9UWEtlVTRDSXZFaGRFbUZRenl5TngxTTRXeTZ2blVoeEJMczQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brazil grants NeuroSense ALS drug patent protection through 2042", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPQl83RWcyelg4aVZ5RVhtN1FwS1FQTVFyQTJNb1EySFpxNUttclg3VGVMSlAtX1ZldlpNbG12LVBwNTduUzc0c0lUSE1IdE00c00tMW1XdDUwTzU4WG9mbElNci1fUEpmRDRTSDJmTHF3NE5EQ0plZDlydVUtY2FDZlllVDlyekNwTmhQbFdUSHdsMzg4NlN0cUZlczlnWEFLd2F6WHdpQklVZ25S?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxOQ3puQUwyd0ZhZlZITUJQcXN4cjdocjB5a19ESzBxSms0U3RReFdBXzhCS3FxMkNOUDl0Q2FNTHdBenJLeUZjc2NEaHNuQmdnbW9iVFFOUkFIM2NiTHg0UURZa21WdUkwVWhqNmpoWUxaLXBiYkVXbFFYSDJnV1BJRGdoX3NfeGtYN1FnTHQ2bHV6OVpfS3IxUlVhSk55WGhNSkxEaUJHWndxT21OSm50eWl5bjdnUEZNcm4tNUdaRThtSjRLX0h0eGhBVE9uUUpDWTFGdjBsZHREZk9TY083M3dR?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Provides Business Update and Progress for the First Half of 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNMXYxSEs5T2tJVVdyRXZGSl9ad3JZdGNiTHJ5Um1zYmFSckFPM2p6VnBfM3VHclJkNHB4Z0RoV3J3QTFTOFVBVWczeldzei1aenJSUER0OUNES0IzRTRzNDB0aF91RG9uTG1vN09YOU80NVZKMi1jUE1EX1NwRy1WeWZaS1FwSWZzbXpzOEFteHA0Rm9TMUFwQXk4QS1QTUlpTVhhVXhfYVp5R1lxLXFaQnEySl9odmp2WDBMM1V0RmlOYy1QNjM0OXluNA?oc=5", "source_name": "PR Newswire", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9SSXRYZzJvMHBzZFNJMkVZUTVrR0k0UGdta3F6YjlVVUtYQUZranFGcXpCSUt1T0UtN3JhNDJPVEw3bjFhUWp5emZ6SjR0NVdKd3dBMG1udTNHUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-12-10T01:38:46+00:00", "published_display": "10 Dec 2021 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 54, "sentiment_summary": {"positive": 12, "negative": 1, "neutral": 41, "score": 57, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 0.68, "latest_week": "2026-07-17", "one_week_move": -6.1, "four_week_move": -15.0, "twelve_week_move": -8.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.256088, "market_dynamics_buy_signal": false, "relative_strength": -37.591105, "fair_value_gap": -36.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.7576, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.1% over one week, -15.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 9}, {"label": "PR Newswire", "count": 9}, {"label": "Market source", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "dars.gov.et", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.1% over one week, -15.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "NeuroSense Reports 14.9-Month Median Survival Benefit for PrimeC"}], "updated_at": "2026-07-23T05:30:59.907418+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}